Recombinant human erythropoietin attenuates weight loss in a murine cancer cachexia model.

van Halteren, H K; Bongaerts, G P A; Verhagen, C A M; Kamm, Y J L; Willems, J L; Grutters, G J; Koopman, J P; Wagener, D J Th

van Halteren, H K; Bongaerts, G P A; Verhagen, C A M; Kamm, Y J L; Willems, J L; Grutters, G J; Koopman, J P; Wagener, D J Th.

Affiliation

van Halteren HK; Department of Internal Medicine, Oosterschelde Hospital, PO Box 106, 4460 BB, Goes, The Netherlands. Hvanhalteren@soz.nl

J Cancer Res Clin Oncol ; 130(4): 211-6, 2004 Apr.

Article in En | MEDLINE | ID: mdl-14745550

Subject(s)

Adenocarcinoma/complications; Cachexia/drug therapy; Erythropoietin/pharmacology; Oxygen/administration & dosage; Weight Loss/drug effects; Adenocarcinoma/metabolism; Animals; Cachexia/etiology; Cachexia/metabolism; Disease Models, Animal; Epoetin Alfa; Erythropoietin/therapeutic use; Glycolysis; Hematocrit; Hemoglobins/metabolism; Inhalation; Mice; Mice, Inbred BALB C; Recombinant Proteins

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Oxygen / Cachexia / Adenocarcinoma / Weight Loss / Erythropoietin Type of study: Etiology_studies Limits: Animals Language: En Journal: J Cancer Res Clin Oncol Year: 2004 Document type: Article Affiliation country: Netherlands Country of publication: Germany

Search on Google

Add to My VHL

XML

PubMed Links